Programme Thesis
DayOne Accelerator funds early-stage HealthTech and TechBio startups that can improve pharmaceutical R&D, offering equity-free mentorship and industry connections to help ventures validate, partner, and commercialize. It exists to bridge the gap between emerging technologies and pharma companies seeking external innovation, leveraging Basel’s life sciences ecosystem.
Selection Criteria
- Stage: pre-incorporation, seed, or Series A; less than $10M in dilutive funding raised
- Relevance: technology must directly improve pharma R&D (discovery, development, testing, commercialization)
- Innovation potential: strong scientific or technical novelty with scalability
- Team: demonstrated expertise and ability to execute; founder background matters
- Collaboration readiness: willingness to engage with pharmaceutical partners
- Commercial viability: clear value proposition and go-to-market potential
Past Winners / Cohort Profiles
- Over 128 ventures supported, including 60+ HealthTech startups focused on pharma innovation
- Notable alumni: InSilicoTrials (in silico clinical trials), Risklick (clinical trial risk prediction), TrialHub (trial site selection), Oncoustics (AI ultrasound diagnostics), Theremia (digital therapeutics), Lemna Bio (biotech)
- Archetype: AI/software platforms that accelerate drug development, reduce costs, or improve trial outcomes; often pre-revenue with strong academic or industry co-founders
Ideal Candidate Fingerprint
A pre-incorporation or seed-stage startup with a novel AI or techbio platform that directly addresses a bottleneck in pharmaceutical R&D—such as drug discovery, preclinical safety, or clinical trial optimization. The team combines deep scientific expertise with entrepreneurial drive, has no dilutive funding, and is eager to collaborate with pharma partners in Basel’s ecosystem.
Recommended Framing
Position Eniola’s venture as a pre-incorporation TechBio startup that uses AI-driven platforms (IMPRINT for addiction-liability screening, TOPOLOGIX for drug-protein interaction via topological data analysis) to transform pharma R&D in addiction and drug safety. Leverage the strong endorsements from leading neuroscientists (Berridge, Gershman, Daw, Mattar) and the provisional patent to demonstrate innovation and scalability, while emphasizing the equity-free, fee-free structure and alignment with DayOne’s focus on discovery tools and enabling technologies.
Watch Out
Applicant is an independent researcher based in Nigeria, not in the EU/France; DayOne is based in Switzerland and may prefer European proximity, though international startups are welcome. The venture is pre-incorporation and has no team bios beyond the founder, which could be a weakness for a startup accelerator. The addiction focus may be niche for pharma R&D, but the platforms (IMPRINT/TOPOLOGIX) have broader applicability.